Our therapies are concentrated within the areas of haematology, immunology, and specialty care.
Within haematology we provide extended half-life recombinant replacement clotting factor treatments for haemophilia A and haemophilia B. The portfolio has also expanded into treatment for thrombocytopenia, rare kidney diseases, diffuse large B-cell lymphoma, and myelofibrosis.
Immunology has been central to our work at Sobi for many years, enabling us to build extensive experience in the field. Our Immunology portfolio addresses auto-inflammatory and auto-immune conditions - serious, disabling or even life-threatening diseases.
In the field of specialty care, we focus on rare genetic and metabolic diseases.
Haematology
The area of haematology covers a wide range of conditions, including those involving red and white blood cells, coagulation and platelets, and bone marrow.
Immunology
The field of immunology has long been at the heart of what we do at Sobi, allowing us to gain extensive experience over many years.
Specialty care
We provide therapies for rare genetic and metabolic diseases as well as a number of specialist indications.
Development Pipeline
We see innovation as essential to our vision of
being a global leader in rare diseases. We need
to reinvest in research and development to
continue to provide innovative treatments.